Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Madhu, A.
- Novel Therapies to Combat HIV: A Review
Abstract Views :321 |
PDF Views:0
Authors
Affiliations
1 P.G. Department of Pharmacology, Shree Siddaganga College of Pharmacy, Tumkur-572102, IN
1 P.G. Department of Pharmacology, Shree Siddaganga College of Pharmacy, Tumkur-572102, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 1, No 1 (2009), Pagination: 1-6Abstract
No Abstract.
References
- Myron CS, Nick H, Jay LA, Kevin DC, Joep Lange. The spread, treatment and prevention of HIV-1. J Clin Invest.2008:1244-54.
- Zheng NN, Kiviat NB, Sow PS, Hawes SE, Wilson A, Diallo-Agne H. Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1 and HIV-2-infected individuals in senegal. J Virol. 2004:13934–42.
- Jose MC, Michael F, Daniel PC, Paul MJ, William OC. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. 2006: 3289– 96
- Qi G, Hsu-Tso H, Ira D, Li F, Nannan Z, Jacques F,et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J virol. 2003:10528–36.
- Hsu-Tso H, Li F, Beata NS, Brian MA, Chang-Ben L, Gregory Y,et al. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J Virol. 2006:4017–25.
- Phogat S, Wyatt RT, Karlsson HGB. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J Intern Med. 2007: 26–43.
- John MP, Robert DW. The entry of entry inhibitors. A fusion of science and medicine. 2003: 19.
- Tonie C, Jabulani N, Mia C, Dragana O, Thomas K, William OC, et al. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol. 2003: 4449–56.
- Rachel B, Johanne M. Association between disruption of CD4 receptor dimerization and increased human immunodeficiency virus type 1 entry. Retrovirology. 2006: 31.
- Won-TC, Shaomin T, Chang-Zhi D, Santosh K,Dongxiang L, Navid M, et al. Unique ligand binding sites on CXCR4 probed by a chemical biology approach. J Virol. 2005: 15398–404.
- Hans SP, Sarah S, Bruce DJ, Jeffrey JM. New approaches in the treatment of HIV/AIDS –focus on maraviroc and other CCR5 antagonists. Therapeutics and Clinical Risk Management. 2008: 473–85.
- George, Frederic B, Josephine R, Robert DW, James HA. Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Envelope Proteins. J Virol. 2003: 931–42.
- Chih-chin H, Min T, Mei-Yun Z, Shahzad M, Elizabeth M, Robyn SL, et al. Structure of a V3-containing HIV-1 gp120 core. Science. 2005: 1025-28.
- Quan-en Y, Andrew SG, Joseph AW, Paula RE, Weimin Z, Michael CJ, et al. Discovery of small molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. J Virol, 2005: 6122–33.
- Emily PJ, James DP, David K. Efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Virol, 2005: 4347–56.
- Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005: 549–55.
- Jacqueline RD, Stephen GA, Navid A, John ML, Phoebe HE, Matthew S, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope_coreceptor affinity, receptor density, and fusion kinetics. PNAS. 2002: 16249–54.
- Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science. 2004: 485–7.
- Xing-Quan Z, Meredith S, Michael F, Robert ST. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (t-20).Science. 2006: 2231–3.
- Christina KMR, Miriam N, Scott KG, Paul K. Enfuvirtide antiretroviral therapy in HIV-1 infection. Therapeutics and Clinical Risk Management. 2008: 433–9.
- Ping Z, William C, Olson, Kenneth H. Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes. J Virol. 2001: 6682–6.
- Jeffrey MJ, Robert JI, Israel L, Nancy AO, Linda SV, Melanie B, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother. 2004: 423–9.
- Navid M, Ana LP, Kumar S, Jason MC, Jason JC, Judith LL, et al. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol. 2004: 3742–52.
- Zhihai S, Navid M, Jason MC, Jason JC, Jeffrey CK, Arne S, Ngoc P, et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A. 2004: 5036–41.
- Michelle M, Jing L, Steven DG, Rainer Z, Danie KR. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations. J of Clinical Microbiology. 2006: 3384–7.
- Hans PS, Sarah S, Bruce JD, Jeffrey MJ. New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists. Ther Clin Risk Manag. 2008: 473–85.
- Cecile LT, Françoise Gl, Christopher K, Yongbiao G, Ting-Chao C, Bahige MB, et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother. 2002: 1336–9.
- Surendiran A. Entry Inhibitor - Maraviroc in HIV treatment. Jipmer. 2008: 3-4.
- Julie MS, Cecile T, Serena X, Lisa W, Nicole W, Waldemar G, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005: 4911-9.
- Alonso H, Bruce G, Olga L, Nhut L, Douty B, Anthony D, et al. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother. 2007: 2489–96.
- Christina MRK, Miriam N, Scott GK, Paul K. Enfuvirtide antiretroviral therapy in HIV-1 infection. Therapeutics and Clinical Risk Management. 2008: 433–9.
- Hartmut S, Charlotte K, Nele P, Antje B, Guido K, Christian H, et al. Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. Antimicrob Agents Chemother. 2006: 667–73
- Michelle M, Jing L, Steven DG, Rainer Z, Daniel KR. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations. J of clinical microbiology. 2006: 3384–7.